BioSante Pharmaceuticals to Present at International Society for the Study of Women's Sexual Health and Sachs Biotech Conferences
BioSante will also be participating in the 5th Annual North American Forum for Investing & Partnering in Biotech and Medtech, sponsored by Sachs Associates, to be held March 13-14, 2006 at the Fairmont Copley Plaza in Boston. Mr. Simes will provide a corporate overview on Monday, March 13 at 11:55 a.m. ET.
“Bio-E-Gel(TM), A Transdermal Estradiol Gel, Effectively Treats Postmenopausal Vasomotor Symptoms”
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was submitted to the FDA on February 16, 2006. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma Inc. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at: www.biosantepharma.com.